Trials / Completed
CompletedNCT04391959
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Azura Ophthalmics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
Detailed description
AZ202001 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study evaluating the safety, efficacy and tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZR-MD-001 Active | AZR-MD-001 is an active ophthalmic ointment |
| DRUG | AZR-MD-001 Vehicle | AZR-MD-001 is a vehicle ophthalmic ointment |
Timeline
- Start date
- 2020-07-17
- Primary completion
- 2021-01-06
- Completion
- 2021-01-06
- First posted
- 2020-05-18
- Last updated
- 2022-05-16
- Results posted
- 2022-05-16
Locations
5 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT04391959. Inclusion in this directory is not an endorsement.